Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Readily available clinical parameters can identify those at greatest risk for hepatocellular carcinoma.
While women have a lower risk for NAFLD, once present, the disease advanced more rapidly.
About a quarter of people taking a higher dose of Ocaliva saw an improvement in liver fibrosis.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.